Divestments

Fertin Pharma

Deliver active ingredients effectively and pleasantly

Fertin Pharma develops and manufactures pharmaceutical and nutraceutical products for leading global companies to support healthier living

  • Sektor
    Healthcare
  • Land
    Denmark
  • Ansvarig Advisor
    Rikke Kjær Nielsen
  • Fond
    EQT Mid Market Europe
  • Entry
    2017
  • Web
  • Exit
    2021-07-01
  • Societal Contribution

  • 1No poverty
  • 3Good health and well-being

About Fertin Pharma
Fertin Pharma helps customers create effective, convenient and pleasant high-quality products based on their innovative oral and intra-oral delivery systems including compressed and extruded gum, lozenges, ZapLiq® and pouch powder.

Fertin’s product portfolio has a broad variety of current and possible application areas including Nicotine Replacement Therapy, oral care, gastrointestinal, pain and allergy management, cough and cold and much more.

Fertin supports brand owners and retailers through partners in developing new and innovative products. As an example, its unique combination of more than 100 years of confectionary heritage, profound nicotine knowledge and pharma manufacturing capabilities has made the company the largest independent manufacture of medicated chewing gum in the world.

The company employs more than 700 people across R&D centers and manufacturing facilities in Canada, India and Denmark.

EQT acquired Fertin Pharma in January 2017 and thus entered a partnership with the Bagger-Sørensen family, who still holds a 30% interest in the company.

Prenumerera

Prenumerera på EQT:s press releaser, regulatoriska press releaser och updates.

Typ av nyheter
Preferred language
EQT logo
En syftesdriven global investeringsorganisation
© EQT AB 2021. EQT AB (PUBL). REGISTRATED OFFICE IN STOCKHOLM, SWEDEN. REGISTRATION NUMBER: 556849-4180